| 1 |
34845001 | Network Analysis Identifies Regulators of Basal-Like Breast Cancer Reprogramming and Endocrine Therapy Vulnerability. | 2022 Jan 15 |
1 |
| 2 |
34911733 | Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer. | 2022 Apr 1 |
1 |
| 3 |
35195972 | [GENOMIC PROFILING IN LUMINAL BREAST CANCER]. | 2022 Feb |
4 |
| 4 |
35418303 | Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells. | 2022 Apr 13 |
1 |
| 5 |
35563193 | The Divergent Effects of Ovarian Steroid Hormones in the MCF-7 Model for Luminal A Breast Cancer: Mechanistic Leads for Therapy. | 2022 Apr 27 |
1 |
| 6 |
33011748 | TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. | 2021 Apr |
1 |
| 7 |
33894309 | Nuclear translocation of MRTFA in MCF7 breast cancer cells shifts ERα nuclear/genomic to extra-nuclear/non genomic actions. | 2021 Jun 15 |
2 |
| 8 |
34073233 | KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer. | 2021 May 26 |
1 |
| 9 |
34517157 | Gene expression analysis of invasive breast carcinoma yields differential patterns in luminal subtypes of breast cancer. | 2021 Dec |
1 |
| 10 |
34609431 | Analysis of breast cancer subtypes and their correlations with receptors and ultrasound. | 2021 Jan-Mar |
2 |
| 11 |
34707101 | NRIP1 is activated by C-JUN/C-FOS and activates the expression of PGR, ESR1 and CCND1 in luminal A breast cancer. | 2021 Oct 27 |
1 |
| 12 |
34725332 | ARSD, a novel ERα downstream target gene, inhibits proliferation and migration of breast cancer cells via activating Hippo/YAP pathway. | 2021 Nov 2 |
1 |
| 13 |
34831189 | Positive Regulation of Estrogen Receptor Alpha in Breast Tumorigenesis. | 2021 Oct 31 |
2 |
| 14 |
34845227 | Compressive stress-mediated p38 activation required for ERα + phenotype in breast cancer. | 2021 Nov 29 |
2 |
| 15 |
34944881 | The Estrogen Receptor α Signaling Pathway Controls Alternative Splicing in the Absence of Ligands in Breast Cancer Cells. | 2021 Dec 13 |
1 |
| 16 |
31610144 | Amphiregulin mediates the hormonal regulation on Rspondin-1 expression in the mammary gland. | 2020 Feb 1 |
6 |
| 17 |
31932695 | ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. | 2020 Feb |
1 |
| 18 |
32531861 | Molecular expression and identification of caprine estrogen receptor gene 1 for fertility status in bucks. | 2020 Sep |
1 |
| 19 |
32548262 | Estrogen induces dynamic ERα and RING1B recruitment to control gene and enhancer activities in luminal breast cancer. | 2020 Jun |
1 |
| 20 |
32771039 | Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance. | 2020 Aug 8 |
2 |
| 21 |
33000282 | Knockdown of E2F5 induces cell death via the TP53‑dependent pathway in breast cancer cells carrying wild‑type TP53. | 2020 Nov |
1 |
| 22 |
33123289 | The deubiquitinating enzyme USP1 modulates ERα and modulates breast cancer progression. | 2020 |
1 |
| 23 |
33412751 | The nature of triple-negative breast cancer classification and antitumoral strategies. | 2020 Dec |
2 |
| 24 |
33511077 | Hormonal Receptor Immunochemistry Heterogeneity and 18F-FDG Metabolic Heterogeneity: Preliminary Results of Their Relationship and Prognostic Value in Luminal Non-Metastatic Breast Cancers. | 2020 |
1 |
| 25 |
30315845 | Inhibition of BTF3 sensitizes luminal breast cancer cells to PI3Kα inhibition through the transcriptional regulation of ERα. | 2019 Jan |
1 |
| 26 |
31422497 | Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes. | 2019 Nov |
1 |
| 27 |
29301444 | The search of CAR, AhR, ESRs binding sites in promoters of intronic and intergenic microRNAs. | 2018 Feb |
1 |